Data-driven drug discovery
for the AI and automation era
Accelerate your journey from promising targets to viable candidates with PACE™ – LCC’s data-driven technology platform, combining a chemically-poised, 3D-rich fragment library with automated synthesis.
The right data for the right decisions
Traditional fragment-based drug discovery (FBDD) is proven, but slow. Through AI and automation capabilities, our technology gives you the volume and quality of data needed to rapidly accelerate your progress.
Design meets automation
With fragment libraries expanding, screening for quality hits has become increasingly resource-intensive, making hit-shortlisting more challenging. PACE™ streamlines the hit expansion process by seamlessly integrating rational drug-design with AI capabilities and over 250 automated machines.
Partners in discovery
Every project is different. To get you the data you need, we first need to understand your goals and preferences. This forms the basis of every collaboration, providing direction for how we approach the project and working practices that are fit for your purpose.
In the AI and automation era, drug discovery demands a holistic, connected approach – that’s what PACE™ gives you.
See PACE™ in action
Discover how PACE™ was used to identify a single-digit nM lead compound in two DMTA cycles.
What to expect from PACE™
From data overload to
targeted intelligence
Move beyond sifting through endless, flat compound data. Our 3D-rich, poised fragment library and AI prioritisation deliver high-quality hits for diverse targets, focusing your resources on the most promising leads from the start.
From identified hit to
rapid progression
Eliminate the dead end of a fragment that can't be optimised. Every hit from our library is designed with accessible handles, enabling our automated platform to quickly generate follow-up compounds and accelerate the path to a lead.
From disconnected steps
to integrated cycles
Break the cycle of waiting on external partners and data. Our unified platform combines chiral expertise, medicinal chemistry design, and automated synthesis in closed-loop DMTA cycles to deliver candidate-quality molecules faster.
About LCC
LCC is a platform technology partner for biopharma companies seeking to develop first-in-class and best-in-class small molecule therapeutics. We generate the quality and volume of data needed to accelerate your discovery.
Molecular Glue Degrader (MGD) partnership
Alongside our parent company XtalPi, we offer a dedicated, end-to-end platform for Molecular Glue Degrader (MGD) discovery.
Using LCC’s chiral, 3D-rich design, AI-expansion and automated synthesis alongside XtalPi's proprietary physics-based AI models for protein-protein interface prediction, we can systematically discover
Ready to discuss your next project?
Our proprietary technology platform is built for your most challenging targets. If you’re ready for a data-driven, connected approach to drug discovery, schedule a call today.